• Je něco špatně v tomto záznamu ?

Bladder and upper urinary tract cancers as first and second primary cancers

G. Zheng, K. Sundquist, J. Sundquist, A. Försti, O. Hemminki, K. Hemminki

. 2021 ; 4 (6) : e1406. [pub] 20210611

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011783

Grantová podpora
Biomedicum Helsinki-säätiö
201606100057 China Scholarship Council
No 856620 (Chaperon) European Union's Horizon 2020 research and innovation program, grant
Finska läkaresällskapet grants
The Swedish Research Council

BACKGROUND: Previous population-based studies on second primary cancers (SPCs) in urothelial cancers have focused on known risk factors in bladder cancer patients without data on other urothelial sites of the renal pelvis or ureter. AIMS: To estimate sex-specific risks for any SPCs after urothelial cancers, and in reverse order, for urothelial cancers as SPCs after any cancer. Such two-way analysis may help interpret the results. METHODS: We employed standardized incidence ratios (SIRs) to estimate bidirectional relative risks of subsequent cancer associated with urothelial cancers. Patient data were obtained from the Swedish Cancer Registry from years 1990 through 2015. RESULTS: We identified 46 234 urinary bladder cancers (75% male), 940 ureteral cancers (60% male), and 2410 renal pelvic cancers (57% male). After male bladder cancer, SIRs significantly increased for 9 SPCs, most for ureteral (SIR 41.9) and renal pelvic (17.2) cancers. In the reversed order (bladder cancer as SPC), 10 individual FPCs were associated with an increased risk; highest associations were noted after renal pelvic (21.0) and ureteral (20.9) cancers. After female bladder cancer, SIRs of four SPCs were significantly increased, most for ureteral (87.8) and pelvic (35.7) cancers. Female bladder, ureteral, and pelvic cancers associated are with endometrial cancer. CONCLUSIONS: The risks of recurrent urothelial cancers were very high, and, at most sites, female risks were twice over the male risks. Risks persisted often to follow-up periods of >5 years, motivating an extended patient follow-up. Lynch syndrome-related cancers were associated with particularly female urothelial cancers, calling for clinical vigilance.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011783
003      
CZ-PrNML
005      
20220506131538.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cnr2.1406 $2 doi
035    __
$a (PubMed)34114732
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zheng, Guoqiao $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA $1 https://orcid.org/0000000343379017
245    10
$a Bladder and upper urinary tract cancers as first and second primary cancers / $c G. Zheng, K. Sundquist, J. Sundquist, A. Försti, O. Hemminki, K. Hemminki
520    9_
$a BACKGROUND: Previous population-based studies on second primary cancers (SPCs) in urothelial cancers have focused on known risk factors in bladder cancer patients without data on other urothelial sites of the renal pelvis or ureter. AIMS: To estimate sex-specific risks for any SPCs after urothelial cancers, and in reverse order, for urothelial cancers as SPCs after any cancer. Such two-way analysis may help interpret the results. METHODS: We employed standardized incidence ratios (SIRs) to estimate bidirectional relative risks of subsequent cancer associated with urothelial cancers. Patient data were obtained from the Swedish Cancer Registry from years 1990 through 2015. RESULTS: We identified 46 234 urinary bladder cancers (75% male), 940 ureteral cancers (60% male), and 2410 renal pelvic cancers (57% male). After male bladder cancer, SIRs significantly increased for 9 SPCs, most for ureteral (SIR 41.9) and renal pelvic (17.2) cancers. In the reversed order (bladder cancer as SPC), 10 individual FPCs were associated with an increased risk; highest associations were noted after renal pelvic (21.0) and ureteral (20.9) cancers. After female bladder cancer, SIRs of four SPCs were significantly increased, most for ureteral (87.8) and pelvic (35.7) cancers. Female bladder, ureteral, and pelvic cancers associated are with endometrial cancer. CONCLUSIONS: The risks of recurrent urothelial cancers were very high, and, at most sites, female risks were twice over the male risks. Risks persisted often to follow-up periods of >5 years, motivating an extended patient follow-up. Lynch syndrome-related cancers were associated with particularly female urothelial cancers, calling for clinical vigilance.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x epidemiologie $x etiologie $x patologie $7 D009364
650    _2
$a sekundární malignity $x epidemiologie $x etiologie $x patologie $7 D016609
650    _2
$a prognóza $7 D011379
650    _2
$a registrace $x statistika a číselné údaje $7 D012042
650    _2
$a nádory močovodu $x komplikace $x patologie $7 D014516
650    _2
$a nádory močového měchýře $x komplikace $x patologie $7 D001749
651    _2
$a Švédsko $x epidemiologie $7 D013548
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sundquist, Kristina $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA $u Center for Community-Based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan
700    1_
$a Sundquist, Jan $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA $u Center for Community-Based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan
700    1_
$a Försti, Asta $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Hemminki, Otto $u Department of Surgery, University Health Network, Toronto, Ontario, Canada $u Department of Urology, Helsinki University Hospital, Helsinki, Finland $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
700    1_
$a Hemminki, Kari $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $u Center for Primary Health Care Research, Lund University, Malmö, Sweden $u Biomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, Pilsen, Czech Republic
773    0_
$w MED00209152 $t Cancer reports (Hoboken, N.J.) $x 2573-8348 $g Roč. 4, č. 6 (2021), s. e1406
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34114732 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131530 $b ABA008
999    __
$a ok $b bmc $g 1789402 $s 1162981
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 4 $c 6 $d e1406 $e 20210611 $i 2573-8348 $m Cancer reports $n Cancer Rep (Hoboken) $x MED00209152
GRA    __
$p Biomedicum Helsinki-säätiö
GRA    __
$a 201606100057 $p China Scholarship Council
GRA    __
$a No 856620 (Chaperon) $p European Union's Horizon 2020 research and innovation program, grant
GRA    __
$p Finska läkaresällskapet grants
GRA    __
$p The Swedish Research Council
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace